Tag: Telisotuzumab Vedotin

This year, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will feature a breadth of new data on emerging antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), particularly across solid tumors and hematologic malignancies. This article synthesizes pivotal findings from AbbVie’s next-generation ADC and TCE platforms—including SEZ6-, PSMA/STEAP1-, c-Met-, and FRα-targeted ADCs—alongside immune checkpoint inhibitor combinations and real-world evidence.

Economy: Failure to Reshore Pharmaceutical Manufacturing: US Approved Drug Manufacturing Shifts to Europe as US Deal Volume Drops

AbbVie has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V/ABBV-399; See Drugmap) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.

During the upcoming European Society for Medical Oncology (ESMO) Congress being held in Barcelona, September 13-17, 2024, expect presentations to include new data on...

New data from AbbVie's innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024).

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for $10.1 Billion

Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in for Patients with Previously Treated Non-Small Cell Lung Cancer

A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...